The price is on a page that is not this seller's
The self-pay ladder recorded on this row was read on the brand product's own savings page. Nothing was visible on load: the page's text was a fraction of its full length and every dollar-bearing element measured zero by zero. Selecting the no-insurance tab expanded it more than fifteen-fold and laid the figures out.
A control on the page reveals it, so it is published. But a reader arriving at this seller's front door will not find it there, and this row's price qualifiers name the page they were read on for exactly that reason.
The page that would carry this seller's own full self-pay catalogue could not be read. Its host answered every plain request with a challenge, passed one browser attempt and challenged the next. That page is unread, not empty, and nothing here should be taken as a statement about what it lists.
Two ladders in one block, and they diverge
The same block carries a regular-price ladder and a savings-card ladder. They agree at the bottom two rungs and part company above them, with the card quoting a substantially lower figure at the higher strengths and a stated maximum saving attached to each.
This row quotes the regular price throughout, because that is what applies without the card, and each qualifier names the card figure beside it. A comparison that mixes the two is comparing a list price against a discounted one.
The seller resolves neither against the other on the page, and neither does this site. Both are recorded verbatim.
A month is twenty-eight days, and the page says so
The card defines its own unit in writing. That is unusually honest and it changes the arithmetic: a twenty-eight-day cycle produces thirteen supplies in a calendar year, not twelve. Thirteen of the seventy-three sellers here carry at least one figure that is not a monthly rate, and this is one of them.
The headline strength is the starting dose, and the page states in the same block that the starting dose is not approved as a maintenance dose. So the advertised entry figure is a rung nobody stays on, and the ladder above it roughly doubles.
One presentation is excluded from the headline outright, and the page says which. Three similar products sit behind one number, so the presentation belongs in any comparison made from it.
Approved product, named pharmacy, no state list
Thirteen of the seventy-three sellers here publish brand-name prices and no compounded price at all. This is one of them, and here the manufacturer stands behind the product directly rather than reselling somebody else's figure.
Twenty of the seventy-three sellers here name a dispensing or compounding pharmacy. This seller names its own delivery pharmacy and offers a pharmacy of the buyer's choosing as an alternative, which is a real disclosure on an approved-product route because the dispensing party is also the party setting the price.
Forty-one of the seventy-three sellers here publish no service area, and this is one of them. What exists instead is a residency condition covering the United States and Puerto Rico, which answers a different question from which states a service reaches.
The seller also states its own structure plainly: the clinicians who see patients are independent service providers, and it says it does not influence their prescribing decisions. No individual clinician is named.
A warning letter about this drug line
Eight of the seventy-three sellers here carry a recorded FDA warning letter. This one, from September 2025, concerns a direct-to-consumer video about the tirzepatide brands. The agency's stated reasoning was that the video grossly misrepresented their safety profile and omitted a contraindication from the boxed warning.
The number, the date and a link to the agency's own text are on this row. A warning letter is a disclosure, not a finding of guilt, and it is not treated here as a reason to exclude a company or to score it down.
Worth knowing while reading this roster: the other manufacturer selling directly to patients carries a letter of the same date, on the same reasoning, about the same video. That is a fact about how this market advertised in one particular year rather than about either company alone.
LillyDirect's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (brand) | $299The seller's own regular self-pay price, quoted verbatim: "Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg". ⚠ NOT A CALENDAR MONTH — the page defines its own unit: "One month is defined as 28 days". The card covers "a 1-month prescription of the Zepbound KwikPen for single-patient use or 4 vials", states that "2.5 mg is a starting dose and is not approved as a maintenance dose", and excludes a third presentation outright: "The $299 per month is for the Zepbound KwikPen or vial, not Zepbound single-dose Pen." Under the Savings Card the same strength is quoted "as low as $299 ... subject to a maximum monthly savings of up to $215". "Additional taxes and fees may apply." | September 2026source |
| Tirzepatide (brand) | $399The second rung of the published regular ladder: "$399 for 5 mg", for a supply the page defines as 28 days rather than a calendar month. The Savings Card line quotes the same figure at this strength — "Pay as low as $399 ... 5 mg ... up to $115" — so this is the one rung where the two ladders on the page agree. | September 2026source |
| Tirzepatide (brand) | $499The regular price at this strength: "$499 for 7.5 mg", per 28 days. ⚠ The same block also states "Pay as low as $449 ... 7.5 mg ... subject to a maximum monthly savings of up to $65" under the Savings Card, so the page carries two different figures for one strength and this row quotes the one that applies without the card. | September 2026source |
| Tirzepatide (brand) | $699The top of the published regular ladder, flat across the three highest strengths: "$699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg", per 28 days. ⚠ The Savings Card line quotes these three strengths together at a far lower figure — "Pay as low as $449 ... 10 mg, 12.5 mg, or 15 mg ... up to $271" — which is the widest gap between the two ladders on the page. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 73 providers reviewed here are paid partners today; the other 69 are not. See how this works.
See LillyDirect's current price →Good fit if
- Readers who want the manufacturer's own regular self-pay price for an approved tirzepatide, with every dose strength published.
- Buyers who will count twenty-eight-day supplies rather than calendar months, and want that stated by the seller instead of assumed.
- People who want to check what a telehealth platform quotes them against the figure the manufacturer publishes directly.
- Anyone who wants the dispensing pharmacy named and an alternative pharmacy allowed.
Look elsewhere if
- Anyone who needs a compounded route. There is none here at all.
- Readers who need their state confirmed before starting. What is published is a residency condition, not a coverage list.
- Buyers relying on the headline figure as a maintenance price. It belongs to a starting dose the page itself says is not a maintenance dose.
- People who want one unambiguous price. Two ladders sit in the same block and disagree above the second rung.
How this review was verified
- Operated the no-insurance tab by its own visible label, one control at a time, and compared the page's visible text length before and after, because a blanket clicker had previously collapsed this page rather than opening it.
- Recorded the regular-price ladder and named the savings-card figure inside each qualifier, rather than picking whichever number was lower.
- Recorded the seller's own definition of a month as twenty-eight days and set the row's period accordingly, so no template prints a monthly suffix beside a figure that is not monthly.
- Named the page each figure was read on in every qualifier, because that page belongs to the brand product rather than to this seller.
- Recorded this seller's own pharmacy catalogue as unread rather than as absent. The host answered plain requests with a challenge at every depth, passed one browser attempt and challenged the next, so an absence claim on it would be worthless.
- Probed the host that did serve the price with a nonsense path at two depths in the same run as the reading; both returned a genuine not-found page.
- Read the terms of use at the address the site's own link resolves to, and took the governing-law clause and the notice address from it verbatim.
- Searched the agency's published warning-letter record for the named company, 2017 to 2026, with a positive and a negative control in the same pass, and read every returned row. That search covers warning letters only; untitled letters are published separately and were not searched.